Kairos Pharma, Ltd. (KAPA)

Kairos Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	5.58	1.27	0.09	0.44	0.07
Cash & Short-Term Investments	5.58	1.27	0.09	0.44	0.07
Cash Growth	73.30%	1267.74%	-78.72%	498.63%	-
Prepaid Expenses	0.02	0.04	0.01	-	-
Other Current Assets	1.06	2.86	-	-	-
Total Current Assets	6.66	4.17	0.1	0.44	0.07
Other Intangible Assets	0.1	0.22	0.38	0.54	0.7
Long-Term Deferred Charges	1.31	1.38	0.48	0.06	-
Total Assets	8.07	5.77	0.97	1.04	0.78
Accounts Payable	0.4	0.99	2.4	1.63	1.55
Short-Term Debt	-	-	0	0	0.39
Total Current Liabilities	0.4	0.99	2.41	1.63	1.94
Long-Term Debt	-	-	0.64	0.58	-
Total Liabilities	0.4	0.99	3.04	2.22	1.94
Common Stock	0.02	0.01	0.01	0.01	0.1
Additional Paid-In Capital	20.54	13.58	4.12	3.21	2.08
Retained Earnings	-12.9	-8.82	-6.21	-4.4	-3.35
Shareholders' Equity	7.66	4.78	-2.08	-1.18	-1.17
Total Liabilities & Equity	8.07	5.77	0.97	1.04	0.78
Total Debt	-	-	0.64	0.59	0.39
Net Cash (Debt)	5.58	1.27	-0.55	-0.15	-0.32
Net Cash Per Share	0.34	0.11	-0.05	-0.01	-0.04
Filing Date Shares Outstanding	20.82	16.69	10.56	10.33	9.15
Total Common Shares Outstanding	20.82	13.74	10.56	10.33	9.15
Working Capital	6.25	3.18	-2.3	-1.2	-1.87
Book Value Per Share	0.37	0.35	-0.20	-0.11	-0.13
Tangible Book Value	7.56	4.55	-2.46	-1.72	-1.87
Tangible Book Value Per Share	0.36	0.33	-0.23	-0.17	-0.20

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q